Carregando...

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

Since its approval by the US Food and Drug Administration in February 2002, the tyrosine kinase inhibitor, imatinib, has become the standard of care for patients with metastatic or unresectable KIT-positive gastrointestinal stromal tumors (GISTs). Imatinib functions by blocking the adenosine triphos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Kee, Damien, Zalcberg, John R.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3424497/
https://ncbi.nlm.nih.gov/pubmed/22942908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834012450935
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!